New drug cocktail shows promise against Hard-to-Treat HPV cancers
NCT ID NCT04287868
First seen Apr 25, 2026 · Last updated Apr 25, 2026
Summary
This study tests whether a mix of three immunotherapy drugs can shrink tumors in people with advanced HPV-related cancers, such as cervical, anal, and throat cancers. About 51 adults with cancer that has spread or cannot be removed will receive the drugs for up to one year. The goal is to control the disease, not cure it, and researchers will monitor side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.